Acrivon Therapeutics, Common Stock Investor Sentiment

ACRV Stock   5.46  0.15  2.67%   
Slightly above 85 percent of Acrivon Therapeutics,'s sophisticated investors are selling. The analysis of the overall investor sentiment regarding Acrivon Therapeutics, Common suggests that a fairly large number of traders are terrified. Acrivon Therapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Acrivon Therapeutics,'s earnings reports, geopolitical events, and overall market trends.
  

Acrivon Therapeutics, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Acrivon Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at www.macroaxis.com         
Acquisition by Miller Mary of 3858 shares of Acrivon Therapeutics, subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Cantor Fitzgerald Initiates Coverage on Acrivon Therapeutics
news
over two months ago at www.macroaxis.com         
Disposition of 659 shares by Miller Mary of Acrivon Therapeutics, at 5.78 subject to Rule 16b-3
Macroaxis News
over three months ago at investing.com         
Acrivon Therapeutics SWOT analysis oncology innovators stock faces pivotal phase
Investing News at Macroaxis
over three months ago at news.google.com         
Acrivon Therapeutics SWOT analysis oncology innovators stock faces pivotal phase - Investing.com UK
Google News at Macroaxis
over three months ago at news.google.com         
Acrivon Therapeutics Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Google News at Macroaxis
over three months ago at investing.com         
Acrivon Therapeutics SWOT analysis oncology biotech stocks platform potential
Investing News at Macroaxis
over three months ago at thelincolnianonline.com         
Acrivon Therapeutics, Inc. Receives 23.67 Consensus Price Target from Analysts
news
over three months ago at www.macroaxis.com         
Disposition of 19910 shares by Blume-jensen Peter of Acrivon Therapeutics, at 6.44 subject to Rule 1...
Macroaxis News
over three months ago at simplywall.st         
Were Not Very Worried About Acrivon Therapeutics Cash Burn Rate
Simply Wall St News at Macroaxis
over three months ago at gurufocus.com         
Sands Capital Ventures, LLC Amplifies Stake in Klaviyo Inc
Gurufocus Stories at Macroaxis
over three months ago at investing.com         
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments
Investing News at Macroaxis
over three months ago at investing.com         
Disposition of 490 shares by Blume-jensen Peter of Acrivon Therapeutics, at 7.92 subject to Rule 16b...
Investing News at Macroaxis
over three months ago at seekingalpha.com         
Acrivon Therapeutics GAAP EPS of -0.59
seekingalpha News
over three months ago at globenewswire.com         
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Acrivon Therapeutics, that are available to investors today. That information is available publicly through Acrivon media outlets and privately through word of mouth or via Acrivon internal channels. However, regardless of the origin, that massive amount of Acrivon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Acrivon Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Acrivon Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Acrivon Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Acrivon Therapeutics, alpha.

Acrivon Therapeutics, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 659 shares by Miller Mary of Acrivon Therapeutics, at 5.78 subject to Rule 16b-3
01/17/2025
2
Acquisition by Miller Mary of 3858 shares of Acrivon Therapeutics, subject to Rule 16b-3
01/31/2025
3
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 ...
02/05/2025
4
Disposition of 579 shares by Blume-jensen Peter of Acrivon Therapeutics, at 5.42 subject to Rule 16b-3
02/14/2025
5
Disposition of 217 shares by Miller Mary of Acrivon Therapeutics, at 5.42 subject to Rule 16b-3
02/19/2025
6
Disposition of 19904 shares by Blume-jensen Peter of Acrivon Therapeutics, at 5.54 subject to Rule 16b-3
02/21/2025
7
Acquisition by Blume-jensen Peter of 140540 shares of Acrivon Therapeutics, at 5.31 subject to Rule 16b-3
02/28/2025
8
Disposition of 490 shares by Blume-jensen Peter of Acrivon Therapeutics, at 7.92 subject to Rule 16b-3
03/03/2025
9
Analysts Set Acrivon Therapeutics, Inc. Price Target at 23.67
03/18/2025
10
Acrivon Therapeutics SWOT analysis innovative oncology firms stock potential - Investing.com India
03/24/2025

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.